VERO Stock Price Prediction Target 2026 to 2035:- In the high-stakes world of medical technology, few companies provoke as much debate as Venus Concept Inc. (NASDAQ: VERO). As a global player in the medical aesthetic and hair restoration space, the company has navigated a turbulent path marked by debt restructuring, strategic divestitures, and a relentless focus on innovation.
As we look toward the next decade, the VERO Stock Price is inextricably linked to the company’s ability to pivot toward its core aesthetics business and achieve sustainable profitability. As of mid-January 2026, the stock is trading near $1.43, reflecting a micro-cap valuation that is either a “ground-floor” opportunity or a cautionary tale of the capital equipment market.
This forecast analyzes the VERO Stock Price prediction from 2026 to 2035, examining the catalysts that could spark a recovery and the risks that continue to weigh on the balance sheet.
2026 Forecast: The “Turnaround” Year
2026 is the most critical year in Venus Concept’s modern history. Following the 1-for-11 reverse stock split in early 2025 and the ongoing divestiture of its “Venus Hair” business, the company is attempting to emerge as a leaner, aesthetics-only powerhouse.
Key Drivers for 2026
- Venus NOVA Commercialization: The recent FDA 510(k) clearance for Venus NOVA is the primary catalyst. This next-generation platform for body, face, and skin treatments is expected to drive sequential revenue growth throughout 2026 as it reaches full global distribution.
- Debt-to-Equity Transformation: Throughout 2025, the company aggressively exchanged debt for preferred stock (notably with Madryn Asset Management). If this continues in 2026, it will drastically lower interest expenses, improving the net loss profile.
- Revenue Stabilization: Analysts project 2026 revenue to climb toward $124 million, a significant leap if the company can overcome the macroeconomic headwinds that dampened 2025 sales.
2026 Price Prediction: If the Venus NOVA launch is successful, the VERO Stock Price could target a recovery toward the $5.00 – $8.00 range, assuming market sentiment for micro-cap med-tech improves.
Mid-Term Outlook: VERO Stock Price (2027 – 2030)
The window between 2027 and 2030 will determine if Venus Concept can graduate from a “struggling micro-cap” to a stable “small-cap” contender.
Structural Shift to Subscriptions
By 2028, the company aims to have a larger percentage of its revenue coming from recurring subscription models rather than one-time equipment sales.
- Cash Flow Positivity: The “holy grail” for VERO is positive Adjusted EBITDA. Most models suggest that if the company can maintain a 65%+ gross margin and keep operating expenses flat, it could reach this milestone by 2028.
- Weight Loss Market Synergy: Venus Concept has signaled interest in the GLP-1 weight loss medication market. By positioning its body-contouring devices (like BlissMax) as a “skin tightening” solution for patients losing significant weight via drugs, it could tap into a massive new demographic.
2030 Price Target: In a successful turnaround scenario, the VERO Stock Price could reach $12.00 to $18.00, reflecting a more normalized valuation multiple relative to its med-tech peers.
Long-Term Vision: 2031 – 2035
Predicting the value of a micro-cap stock a decade out requires a “blue sky” approach. By 2035, the medical aesthetics industry is expected to be a $30 billion global market.
The “Aesthetic Utility” Phase
By 2035, the VERO Stock Price will likely be determined by whether the company has become an acquisition target for a larger healthcare conglomerate (like AbbVie or Bausch Health).
- AI-Integrated Aesthetics: By the 2030s, “Venus Connect” (their IoT application) will likely use advanced AI to provide real-time treatment optimization, making their devices indispensable to high-end clinics.
- Global Expansion: If the company successfully penetrates the growing middle-class markets in India and Southeast Asia, its revenue base could be double its current size.
2035 Price Target Range:
- Base Case: $25.00 (Reflecting moderate growth and debt-free operations).
- Bull Case: $45.00+ (Assuming a strategic buyout at a premium).
VERO Stock Forecast Summary Table
| Year | Key Theme | Projected Revenue | Price Target (Avg) |
| 2026 | Venus NOVA Launch | $124M | $6.50 |
| 2028 | Subscription Growth | $145M | $10.00 |
| 2030 | EBITDA Positive | $175M | $15.00 |
| 2035 | M&A Potential | $250M+ | $30.00 |
Key Risks to the VERO Stock Price
Investors must approach Venus Concept with a clear understanding of the risks:
- Liquidity Concerns: As of late 2025, the company had limited cash on hand ($4.9M). Continued “burn” without a capital infusion or successful hair-business sale could lead to further dilution.
- Nasdaq Compliance: Given the low share price, the company has historically struggled with Nasdaq’s minimum bid price requirements. Any future delisting threats would be highly bearish for the VERO Stock Price.
- Macro Headwinds: High interest rates make it difficult for med-spa owners to finance the purchase of expensive capital equipment like the systems Venus Concept sells.
FAQ: Venus Concept Stock Outlook
Why did the VERO stock price drop so much in 2024/2025?
The drop was largely due to a “challenging capital equipment market,” high interest rates, and a heavy debt load. The 1-for-11 reverse split in 2025 was a move to maintain Nasdaq listing requirements.
Is VERO a “Buy” at $1.43?
It is a high-risk, high-reward play. For value investors, the P/B ratio (Price-to-Book) of ~1.28x suggests the stock is undervalued compared to the industry average (~3.92x). However, this must be balanced against its high debt-to-equity ratio.
What happened to the Venus Hair business?
The company entered an agreement to sell it for $20 million to Meta Healthcare Group. As of early 2026, the company is still working to finalize this deal, which has been delayed by legal challenges in the Delaware Court of Chancery.
Does VERO pay dividends?
No. Venus Concept is a growth-oriented medical technology company and has never paid a dividend. All available cash is used to fund R&D and debt reduction.
Conclusion
The story of the VERO Stock Price from 2026 to 2035 is one of survival and transformation. If the management team can successfully commercialize the Venus NOVA platform and exit its high-debt cycle, the current valuation could be seen as a historic entry point.
However, the road is paved with significant volatility. For long-term investors, the focus should remain on quarterly revenue trends and the company’s ability to narrow its net loss. If the “aesthetics-first” strategy pays off, Venus Concept may finally reclaim its status as a leader in medical technology.